|
Vernalis Plc - Company Profile Snapshot
| Company Profile: |
Vernalis Plc |
| Ticker: |
VNLPY |
| Exchanges: |
NAS |
| 2008 Sales: |
18,825,000 |
| Major Industry: |
Drugs, Cosmetics & Health Care |
| Sub Industry: |
Ethical Drug Manufacturers |
| Country: |
UNITED KINGDOM |
| Employees: |
92 |
Business Description
Vernalis Plc. The Group's principal activity is to develop and commercialize pharmaceutical products for a range of medical disorders. It has expertise both in de- novo structure and fragment-based drug discovery and pre-clinical and clinical development. The Group has seven product candidates in clinical development (two of which are partnered), two programmes in pre-clinical (one with a partner) and other competitive research programmes. The Group operates in the United Kingdom, Rest of Europe, North America and Rest of the World. On 01-Jul-2008, the Group completed the sale of Apokyn and Vernalis Pharmaceuticals Inc.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
